Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Strategies to overcome resistance to targeted protein kinase inhibitors in the treatment of cancer.

Drugs in R&D - 1 Jan 2006

Buschbeck Marcus

Abstract excerpt

Inhibition of oncogenic protein kinases by small compound inhibitors has proven to be a valuable strategy for the directed and target-specific treatment of an ever-increasing number of cancer types. These include the treatment of chronic myeloid leukemia with the Bcr-Abl inhibitor imatinib and non-small-cell lung cancer with the epidermal growth factor inhibitors erlotinib and gefitinib. Unfortunately, initially...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Models, Biological

Share to Mutation

Share to Neoplasms

Share to Protein Kinase Inhibitors

Share to Protein-Tyrosine Kinases

Source

Identifiers

PMID: 16542054
DOI: 10.2165/00126839-200607020-00002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Strategies to overcome resistance to targeted protein kinase inhibitors in the treatment of cancer.PMID 16542054Read ↗

Targeted Therapies in Cancer: To Be or Not to Be, SelectiveSemantic proximity Read ↗

Strategies to overcome resistance to targeted protein kinase inhibitorsSemantic proximity Read ↗

Resistance to tyrosine kinase inhibitors: calling on extra forces.Semantic proximity Read ↗

Mechanisms of clinical resistance to small molecule tyrosine kinase inhibitors targeting oncogenic tyrosine kinases.Semantic proximity Read ↗

Strategies to overcome drug resistance of receptor tyrosine kinaseaddicted cancer cells.Semantic proximity Read ↗

Emerging combination therapies to overcome resistance in EGFR-driven tumors.Semantic proximity Read ↗

Dual-Targeted Therapy Circumvents Non-Genetic Drug Resistance to Targeted TherapySemantic proximity Read ↗

Molecular Pathways: Resistance to Kinase Inhibitors and Implications for Therapeutic StrategiesSemantic proximity Read ↗

Mechanisms of drug resistance in kinasesSemantic proximity Read ↗

Strategies to overcome acquired resistances conferred by mutations in the kinase domain of EGFR.Semantic proximity Read ↗

Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapySemantic proximity Read ↗

Mechanisms of acquired resistance to tyrosine kinase inhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.